Dosing of LAIs is complicated by delayed release of drug, changes in plasma levels without change in dose, and by the lack of data establishing clear dose requirements. All LAIs offer the prospect of assured adherence (although patients may still default on treatment) but their use is complicated by adverse effects, complex pharmacokinetics and confusion over dose-response relationships.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- functional connectivity
- electronic health record
- type diabetes
- emergency department
- adverse drug
- machine learning
- big data
- ultrasound guided
- combination therapy
- skeletal muscle
- weight loss
- patient reported